A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

Robert R. Recker, Charles T. Benson, Toshio Matsumoto, Michael A. Bolognese, Deborah A. Robins, Jahangir Alam, Alan Y. Chiang, Leijun Hu, John H. Krege, Hideaki Sowa, Bruce H. Mitlak, Stephen L. Myers

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Sclerostin, a SOST protein secreted by osteocytes, negatively regulates formation of mineralized bone matrix and bone mass. We report the results of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial of blosozumab, a humanized monoclonal antibody targeted against sclerostin, in postmenopausal women with low bone mineral density (BMD). Postmenopausal women with a lumbar spine T-score -2.0 to -3.5, inclusive, were randomized to subcutaneous blosozumab 180mg every 4 weeks (Q4W), 180mg every 2 weeks (Q2W), 270mg Q2W, or matching placebo for 1 year, with calcium and vitamin D. Serial measurements of spine and hip BMD and biochemical markers of bone turnover were performed. Overall, 120 women were enrolled in the study (mean age 65.8 years, mean lumbar spine T-score -2.8). Blosozumab treatment resulted in statistically significant dose-related increases in spine, femoral neck, and total hip BMD as compared with placebo. In the highest dose group, BMD increases from baseline reached 17.7% at the spine, and 6.2% at the total hip. Biochemical markers of bone formation increased rapidly during blosozumab treatment, and trended toward pretreatment levels by study end. However, bone specific alkaline phosphatase remained higher than placebo at study end in the highest-dose group. CTx, a biochemical marker of bone resorption, decreased early in blosozumab treatment to a concentration less than that of the placebo group by 2 weeks, and remained reduced throughout blosozumab treatment. Mild injection site reactions were reported more frequently with blosozumab than placebo. In conclusion, treatment of postmenopausal women with an antibody targeted against sclerostin resulted in substantial increases in spine and hip BMD. These results support further study of blosozumab as a potential anabolic therapy for osteoporosis.

Original languageEnglish
Pages (from-to)216-224
Number of pages9
JournalJournal of Bone and Mineral Research
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Bone Density
Clinical Trials
Spine
Antibodies
Placebos
Pelvic Bones
Biomarkers
Therapeutics
Antibodies, Monoclonal, Humanized
Bone and Bones
Osteocytes
Bone Matrix
blosozumab
Bone Remodeling
Femur Neck
Bone Resorption
Osteogenesis
Vitamin D
Osteoporosis
Alkaline Phosphatase

All Science Journal Classification (ASJC) codes

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. / Recker, Robert R.; Benson, Charles T.; Matsumoto, Toshio; Bolognese, Michael A.; Robins, Deborah A.; Alam, Jahangir; Chiang, Alan Y.; Hu, Leijun; Krege, John H.; Sowa, Hideaki; Mitlak, Bruce H.; Myers, Stephen L.

In: Journal of Bone and Mineral Research, Vol. 30, No. 2, 01.02.2015, p. 216-224.

Research output: Contribution to journalArticle

Recker, RR, Benson, CT, Matsumoto, T, Bolognese, MA, Robins, DA, Alam, J, Chiang, AY, Hu, L, Krege, JH, Sowa, H, Mitlak, BH & Myers, SL 2015, 'A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density', Journal of Bone and Mineral Research, vol. 30, no. 2, pp. 216-224. https://doi.org/10.1002/jbmr.2351
Recker, Robert R. ; Benson, Charles T. ; Matsumoto, Toshio ; Bolognese, Michael A. ; Robins, Deborah A. ; Alam, Jahangir ; Chiang, Alan Y. ; Hu, Leijun ; Krege, John H. ; Sowa, Hideaki ; Mitlak, Bruce H. ; Myers, Stephen L. / A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. In: Journal of Bone and Mineral Research. 2015 ; Vol. 30, No. 2. pp. 216-224.
@article{06d83b044c95462c8747b2d94e99c9ca,
title = "A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density",
abstract = "Sclerostin, a SOST protein secreted by osteocytes, negatively regulates formation of mineralized bone matrix and bone mass. We report the results of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial of blosozumab, a humanized monoclonal antibody targeted against sclerostin, in postmenopausal women with low bone mineral density (BMD). Postmenopausal women with a lumbar spine T-score -2.0 to -3.5, inclusive, were randomized to subcutaneous blosozumab 180mg every 4 weeks (Q4W), 180mg every 2 weeks (Q2W), 270mg Q2W, or matching placebo for 1 year, with calcium and vitamin D. Serial measurements of spine and hip BMD and biochemical markers of bone turnover were performed. Overall, 120 women were enrolled in the study (mean age 65.8 years, mean lumbar spine T-score -2.8). Blosozumab treatment resulted in statistically significant dose-related increases in spine, femoral neck, and total hip BMD as compared with placebo. In the highest dose group, BMD increases from baseline reached 17.7{\%} at the spine, and 6.2{\%} at the total hip. Biochemical markers of bone formation increased rapidly during blosozumab treatment, and trended toward pretreatment levels by study end. However, bone specific alkaline phosphatase remained higher than placebo at study end in the highest-dose group. CTx, a biochemical marker of bone resorption, decreased early in blosozumab treatment to a concentration less than that of the placebo group by 2 weeks, and remained reduced throughout blosozumab treatment. Mild injection site reactions were reported more frequently with blosozumab than placebo. In conclusion, treatment of postmenopausal women with an antibody targeted against sclerostin resulted in substantial increases in spine and hip BMD. These results support further study of blosozumab as a potential anabolic therapy for osteoporosis.",
author = "Recker, {Robert R.} and Benson, {Charles T.} and Toshio Matsumoto and Bolognese, {Michael A.} and Robins, {Deborah A.} and Jahangir Alam and Chiang, {Alan Y.} and Leijun Hu and Krege, {John H.} and Hideaki Sowa and Mitlak, {Bruce H.} and Myers, {Stephen L.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/jbmr.2351",
language = "English",
volume = "30",
pages = "216--224",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

AU - Recker, Robert R.

AU - Benson, Charles T.

AU - Matsumoto, Toshio

AU - Bolognese, Michael A.

AU - Robins, Deborah A.

AU - Alam, Jahangir

AU - Chiang, Alan Y.

AU - Hu, Leijun

AU - Krege, John H.

AU - Sowa, Hideaki

AU - Mitlak, Bruce H.

AU - Myers, Stephen L.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Sclerostin, a SOST protein secreted by osteocytes, negatively regulates formation of mineralized bone matrix and bone mass. We report the results of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial of blosozumab, a humanized monoclonal antibody targeted against sclerostin, in postmenopausal women with low bone mineral density (BMD). Postmenopausal women with a lumbar spine T-score -2.0 to -3.5, inclusive, were randomized to subcutaneous blosozumab 180mg every 4 weeks (Q4W), 180mg every 2 weeks (Q2W), 270mg Q2W, or matching placebo for 1 year, with calcium and vitamin D. Serial measurements of spine and hip BMD and biochemical markers of bone turnover were performed. Overall, 120 women were enrolled in the study (mean age 65.8 years, mean lumbar spine T-score -2.8). Blosozumab treatment resulted in statistically significant dose-related increases in spine, femoral neck, and total hip BMD as compared with placebo. In the highest dose group, BMD increases from baseline reached 17.7% at the spine, and 6.2% at the total hip. Biochemical markers of bone formation increased rapidly during blosozumab treatment, and trended toward pretreatment levels by study end. However, bone specific alkaline phosphatase remained higher than placebo at study end in the highest-dose group. CTx, a biochemical marker of bone resorption, decreased early in blosozumab treatment to a concentration less than that of the placebo group by 2 weeks, and remained reduced throughout blosozumab treatment. Mild injection site reactions were reported more frequently with blosozumab than placebo. In conclusion, treatment of postmenopausal women with an antibody targeted against sclerostin resulted in substantial increases in spine and hip BMD. These results support further study of blosozumab as a potential anabolic therapy for osteoporosis.

AB - Sclerostin, a SOST protein secreted by osteocytes, negatively regulates formation of mineralized bone matrix and bone mass. We report the results of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial of blosozumab, a humanized monoclonal antibody targeted against sclerostin, in postmenopausal women with low bone mineral density (BMD). Postmenopausal women with a lumbar spine T-score -2.0 to -3.5, inclusive, were randomized to subcutaneous blosozumab 180mg every 4 weeks (Q4W), 180mg every 2 weeks (Q2W), 270mg Q2W, or matching placebo for 1 year, with calcium and vitamin D. Serial measurements of spine and hip BMD and biochemical markers of bone turnover were performed. Overall, 120 women were enrolled in the study (mean age 65.8 years, mean lumbar spine T-score -2.8). Blosozumab treatment resulted in statistically significant dose-related increases in spine, femoral neck, and total hip BMD as compared with placebo. In the highest dose group, BMD increases from baseline reached 17.7% at the spine, and 6.2% at the total hip. Biochemical markers of bone formation increased rapidly during blosozumab treatment, and trended toward pretreatment levels by study end. However, bone specific alkaline phosphatase remained higher than placebo at study end in the highest-dose group. CTx, a biochemical marker of bone resorption, decreased early in blosozumab treatment to a concentration less than that of the placebo group by 2 weeks, and remained reduced throughout blosozumab treatment. Mild injection site reactions were reported more frequently with blosozumab than placebo. In conclusion, treatment of postmenopausal women with an antibody targeted against sclerostin resulted in substantial increases in spine and hip BMD. These results support further study of blosozumab as a potential anabolic therapy for osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84921809759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921809759&partnerID=8YFLogxK

U2 - 10.1002/jbmr.2351

DO - 10.1002/jbmr.2351

M3 - Article

VL - 30

SP - 216

EP - 224

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 2

ER -